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CLINICAL INVESTIGATION
Heparin suppresses mesangial cell proliferation and matrix
expansion in experimental mesangioproliferative
glomerulonephritis
JURGEN FLOEGE, EUDORA ENG, BESSIE . YOUNG, WILLIAM G. COUSER,
and RICHARD J. JOHNSON
Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington, USA
Heparin suppresses mesangiat cell proliferation and matrix expansion
in experimental mesangioproliferative glomerulonephritis. Proliferation
and extracellular matrix (ECM) overproduction by glomerular mesan-
gial cells characterizes many types of glomerulonephritis and often
precedes the development of glomerulosclerosis. Heparin is a potent
inhibitor of mesangial cell growth in vitro. We examined whether
standard heparin can inhibit mesangial cell proliferation in vivo in the
mesangioproliferative anti-Thy 1.1 nephritis. Untreated control rats
were compared to rats infused with heparin either early (day —2 to 1) or
late (day 2 to 5) after induction of anti-Thy 1.1 nephritis. The results
show that heparin treatment significantly reduced mesangial cell prolif-
eration regardless of when it was initiated. Heparin (either early or late
treatment) also reduced mesangial basic fibroblast growth factor
(bFGF) expression and platelet-derived growth factor (PDGF) receptor
up-regulation as reflected by immunostaining, whereas PDGF B-chain
expression was reduced only by late heparin treatment. Furthermore,
heparin treatment markedly inhibited the mesangial matrix expansion
for a variety of ECM proteins, including laminin, type I and IV
collagen, fibronectin and entactin. Heparin did not affect the initial
mesangiolysis, glomerular macrophage influx, deposition of anti-Thy
1.1 IgG or fibrinogen, or the glomerular platelet influx. These results
suggest that heparin, via its antiproliferative rather than anticoagulant
effect, can inhibit mesangial cell proliferation, overexpression of
polypeptide growth factors, and ECM protein overproduction in vivo.
The beneficial effect of heparin can be demonstrated even if treatment
is initiated after the development of nephritis. By virtue of these
properties, heparin may be an effective agent in the treatment of human
mesangioproliferative disease and in the prevention of glomeruloscle-
rosis.
One of the key features of various human glomerular dis-
eases, including IgA nephropathy, membranoproliferative gb-
merulonephritis, poststreptococcal glomerulonephritis, vari-
ants of idiopathic focal sclerosis, lupus nephritis, and possibly
diabetic nephropathy, is the proliferation of intrinsic glomerular
mesangial cells [1, 2]. Several experimental studies have sug-
gested that mesangial cell activation and proliferation in vivo
not only results in glomerular hypercellularity but is also
followed by overproduction of extracellular mesangial matrix
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(ECM) [3—7]. Both glomerular hypercellularity and expansion
of the ECM are thought to be of primary importance in the
development of capillary obsolescence and glomerulosclerosis
[8]. The factors involved in the regulation of mesangial cell
proliferation in vitro and in vivo have therefore become the
focus of intense interest.
In contrast to the long list of mesangial cell mitogens in vitro,
few substances exert anti-proliferative effects on these cells
[reviewed in 9]. Among these heparin, heparan sulfate proteo-
glycan, and heparin-like molecules secreted by glomerular
epithelial and endothelial cells have been shown to profoundly
inhibit the growth of mesangial cells [10—12]. In vivo heparin
treatment was able to suppress the formation of hypercellular
mesangial nodules in the focal mesangioproliferative model in
the rat, induced by injection of Habu snake venom [13].
Treatment with heparin has also been shown to reduce the
mesangial hypercellularity that develops in chronic aminonu-
cleoside nephrosis [14] and in the lupus-prone MRL-lpr/lpr mice
[15], while it was unable to affect the endocapillary proliferation
in a model of progressive Masugi nephritis [16] or the nephritis
that develops in the lupus-prone [NZB x NZW]F1 mice [15].
In the present study we have attempted to obtain direct
evidence that heparin can inhibit mesangial cell proliferation in
vivo. One model which has proven to be particularly useful for
the analysis of factors involved in the initiation of mesangial cell
proliferation in vivo and its pathological sequelae is the mesan-
gioproliferative glomerubonephritis induced by injection of an
antibody to the Thy 1.1 antigen [17—19], which is present on the
surface of rat mesangial cells [20]. In this model a single
injection of anti-Thy 1.1 antibody results in rapid, complement-
dependent loss of mesangial cells with disruption of the mesan-
gial matrix ("mesangiolysis"). The early mesangiolysis at day 1
is followed by marked mesangial cell proliferation and expan-
sion of the mesangial extracellular matrix starting at day 2 [3,
191. In this model we have analyzed whether a short course of
heparin treatment instituted either prior to the initiation of
mesangial cell proliferation or at a time when mesangial cell
proliferation is well established, can significantly affect the
gbomerular cell proliferation rate. We have also investigated
whether heparin treatment can affect the expression of mesan-
gial cell growth factors such as platelet-derived growth factor
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(PDGF) and basic fibroblast growth factor (bFGF) and whether
it exerts an influence on the accumulation of mesangial ECM.
The results show that heparin treatment, initiated either prior to
or after the onset of mesangioproliferative nephritis, led to a
potent inhibition of mesangial cell proliferation in anti-Thy 1.1
nephritis, and that it also decreased the overexpression of
glomerular growth factors and ECM proteins. These data
support the hypothesis that cell proliferation, growth factor
expression and ECM synthesis are intricately linked events in
the course of glomerular disease. Heparin, by affecting all these
processes, may therefore present an important therapeutic
agent in the treatment of human mesangioproliferative disease
and in the prevention of glomeruloscierosis.
Methods
Disease model and experimental protocol
The rat anti-Thy 1.1 model [17—19] of mesangial proliferative
glomerulonephritis was induced by injection of goat anti-rat
thymocyte plasma, which was raised as previously described
[19]. Twenty-three male Wistar rats (Bantin-Kingman, Fre-
mont, CA), weighing 180 to 220 g, were studied. As shown in
Figure 1, five rats (group A; untreated anti-Thy 1.1 nephritis)
underwent a sham operation (small abdominal incision) at two
days prior to the intravenous injection of anti-thymocyte
plasma. Renal biopsies were obtained from each rat at days 2
and 6 and at sacrifice (day 10; Fig. 1), The remaining 12 rats
were treated in an identical way, but instead of a sham
operation received an intraperitoneal micro-osmotic pump
(model Alzet 1003D; filling volume 100 j.tl; Alza Corporation,
Palo Alto, California, USA). The pumps were implanted at
either two days prior to the injection of anti-thymocyte plasma
(group B; "early heparin"; N = 6) or at day 2 after the injection
(group C; "late heparin"; N = 6; Fig. 1). The pumps were filled
with heparin sodium (20,000 U/mi; from porcine intestinal
mucosa; Lypho Med, Rosemont, Illinois, USA) and had a
delivery time of 72 hours, that is, heparin was administered
from day —2 to day 1 in group B and from day 2 to day 5 in
group C (Fig. 1). Heparin delivery was calculated as 256 11
U/100 g body wt/day in group B and 254 9 U/100 g!day in
group C. Delivery of heparin was monitored by the determina-
tion of whole blood clotting times (see below) at days —2, 0, 2,
4, 6 and 10. Six additional, non-manipulated Wistar rats were
studied as normal controls.
In an additional control experiment it was assessed whether
heparin treatment and/or the implantation of a micro-osmotic
pump affects food or water intake. For this five rats received
heparin (250 U/100 g body wt) for three days via intrapentoneal
pumps and were compared to five rats which underwent a sham
operation.
In each kidney biopsy the total cell number and the number of
proliferating glomerular cells (as defined by immunostaining for
the proliferating cell nuclear antigen (PCNA) per glomerular
cross section were determined (see below). Mesangial cell
proliferation and activation were assessed by double immuno-
staining for PCNA and Thy 1.1 as well as by immunostaining for
the glomerular de novo expression of a-smooth muscle actin
[2lJ. In addition, immunostaining was performed to detect
glomerular expression of growth factors (PDGF, bFGF) and the
PDGF receptor (/3-subunit), and to assess glomerular ECM
expansion as reflected by immunostaining for type I and IV
collagen, laminin, fibronectin, heparan sulfate proteoglycan,
and entactin. Finally, the number of glomerular monocytes/
macrophages and the presence of glomerular goat IgG (anti-
thymocyte antibody), fibrin/fibrinogen and platelets was deter-
mined by immunohistology.
Renal morphology
Tissue for light microscopy and immunoperoxidase staining
was fixed in methyl Carnoy's solution [19] and embedded in
paraffin. Four jm sections were stained with the periodic acid
Schiff (PAS) reagent and counterstained with hematoxylin. In
the PAS-stained sections the total number of nuclei per glomer-
ular cross section was determined and mesangiolysis was
graded semiquantitatively on a scale from 0 to 4+ as previously
described [21]. A minimum of 20 glomeruli was examined per
biopsy (range 20 to 50).
Iminunoperoxidase staining
Four pm sections of methyl Carnoy's fixed biopsy tissue
were processed by a direct or indirect immunoperoxidase
technique as previously described [191. Primary antibodies
included:
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1. l9A2 (Coulter, Hialeah, Florida, USA), a murine 1gM
monoclonal antibody against human PCNA, which is ex-
pressed by actively proliferating cells [22].
2. a murine monoclonal antibody to an NH2-terminal syn-
thetic decapeptide of a-smooth muscle actin (gift of G.
Gabbiani, Geneva, Switzerland) [23].
3. ED1 (Bioproducts for Science, Indianapolis, Indiana,
USA), a murine monoclonal IgG to a cytoplasmic antigen
present in monocytes, macrophages and dendritic cells.
4. PGF-007 (Mochida Pharmaceutical, Tokyo, Japan) a mu-
rine monoclonal antibody to a 25 amino acid peptide
located near the COOH-terminus of the human PDGF
B-chain [24].
5. a rabbit polyclonal antibody to the /3-subunit of the PDGF-
receptor as described elsewhere [25] (provided by R. Seif-
ert, Seattle, Washington, USA).
6. DE6, a murine monoclonal IgG1 antibody against rh-bFGF
(provided by T. Reilly, DuPont-Merck, Wilmington, Dela-
ware, USA) [26].
7. an IgG fraction of polyclonal rabbit anti-rat laminin (Chem-
icon, Temecula, California, USA).
8. an IgG fraction of polyclonal guinea pig anti-rat type I
collagen [27] (provided by L. Iruela-Arispe, Seattle, Wash-
ington, USA).
9. a biotinylated [28] IgG fraction of polyclonal goat anti-
mouse type IV collagen (Southern Biotech, Birmingham,
Alabama, USA).
10. an affinity-purified IgG fraction of a polyclonal rabbit
anti-rat fibronectin (Chemicon).
11. an IgG fraction of a polyclonal rabbit antibody to mouse
core protein of heparan sulfate proteoglycan (gift of J.R.
Couchman, Birmingham, Alabama, USA) [29].
12. an IgG fraction of polyclonal rabbit anti-mouse entactin!
nidogen (gift of A.E. Chung, Pittsburgh, Pennsylvania,
USA) [30].
13. a polyclonal goat anti-rat fibrinogen antibody (Cappel Lab-
oratories, Cochraneville, Pennsylvania, USA).
14. PL-l, a murine monoclonal antibody against rat platelets
(gift of W.W. Bakker, Groningen, The Netherlands) [31].
For all biopsies, negative controls consisted of substitution of
the primary antibody with equivalent concentrations of an
irrelevant murine monoclonal antibody or normal rabbit IgG.
For each biopsy over 20 cross sections of consecutive corti-
cal glomeruli containing more than 20 discrete capillary seg-
ments each were evaluated by one of the authors, who was
unaware of the origin of the slides. Mean values per biopsy
were calculated for the number of proliferating (PCNA+) cells
and monocytes/macrophages per glomerular cross section. For
the evaluation of the immunoperoxidase stains for a-smooth
muscle actin, PDGF B-chain, PDGF receptor /3-subunit, bFGF
and the various ECM proteins, each glomerulus was graded
semiquantitatively as described previously [3] and the mean
score per biopsy was calculated. Each score reflects mainly
changes in the extent rather than intensity of mesangial matrix
staining:
0 — Diffuse, very weak or absent mesangial matrix stain-
ing. No localized increases of staining.
1 + — Diffuse, weak mesangial matrix staining with up to
25% of the glomerular tuft showing focally increased
staining.
2+ — 25 to 50% of the glomerular tuft demonstrating a focal,
strong staining.
3 + — 50 to 75% of the glomerular tuft stained strongly in a
focal manner
4+ — >75% of the glomerular tuft stained strongly.
Examples of glomerular staining scores of 1 + to 4+ are
provided in Figures 2A to 2D.
For the evaluation of the glomerular deposition of goat IgG or
fibrinogen, or the glomerular platelet influx, each glomerulus
was graded semiquantitatively as showing no deposits or very
rare platelets (grade 0), trace staining or few platelets (grade I),
moderate staining or platelet influx (grade 2), intense staining or
platelet influx (grade 3), or maximal staining or platelet influx
(grade 4).
Immunohistochemical double-staining
Double immunostaining for the identification of the type of
proliferating cells was performed as reported previously [6] by
first staining the sections for proliferating cells with 19A2, an
1gM monoclonal antibody to PCNA, followed by staining with
the IgG1 monoclonal antibody OX-7 (Accurate Chemical Cor-
poration, Westbury, New York, USA), an antibody against the
Thy-l .1 antigen present on the mesangial cell membrane. Iden-
tification of mesangial cells was possible despite the presence of
residual goat anti-thymocyte IgG in the glomerulus suggesting
that either not all Thy 1.1 molecules on the mesangial cell
surface were occupied by the goat antibody or that the mono-
clonal OX-7 antibody recognized a different epitope on the
molecule. Cells were identified as proliferating mesangial cells if
they showed positive nuclear staining for PCNA and if the
nucleus was completely surrounded by cytoplasm or cell mem-
brane positive for OX-7. Proliferating cells in which the PCNA
positive nucleus did not border on the cytoplasm or cell
membrane positive for OX-7 were classified as non-mesangial.
Proliferating (PCNA+) cells which could not be clearly identi-
fied as OX-7 positive or negative were considered non-classifi-
able.
Miscellaneous measurements
Whole blood clotting times were determined using tail vein
blood in glass tubes which were inverted every 25 seconds.
Statistical analysis
All values are expressed as mean SD unless stated other-
wise. Statistical significance (defined as P < 0.05) was evalu-
ated using the Student's t-test or one way analysis of variance
with modified t-tests performed using the Bonferroni correction
[32].
Results
Heparin treatment reduces mesangial cell proliferation in
vivo
Control rats with untreated anti-Thy 1.1 nephritis (group A)
followed the typical disease course as previously reported [3,
19, 21, 25, 33]: total glomerular cell numbers decreased below
normal at day 2 after disease induction, followed by a rapid
increase at days 6 and 10 (Fig. 3). In contrast, glomerular cell
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Fig. 2. Glomerular immunostaining for PDGF receptor 13-subunit at different stages of anti-Thy 1.1 nephritis, illustrating the semiquantitative
scoring system (scores I to IV; see Methods for further details).
proliferation was already increased above the normal range at
day 2 and increased further at day 6 (Fig. 3). At day 10,
glomerular cell proliferation in group A had decreased, but was
still elevated above the normal range (Fig. 3). Double immu-
nostaining for proliferating cells (PCNA+) and mesangial cells
(Thy 1.1+) showed that the majority of proliferating glomerular
cells at days 2, 6 and 10 were of mesangial origin (Table 1). The
mesangial cell proliferation was also associated with de novo
a-smooth muscle actin expression in mesangial regions of
control rats with anti-Thy 1.1 nephritis (group A) at days 2, 6
and 10 (Fig. 4) and was consistent with previous studies [21].
In rats of group B (anti-Thy 1.1 nephritis, early hepann
treatment) the total glomerular cellularity at day 2 was similar to
that observed in group A (Fig. 3). However, both glomerular
cell proliferation and a-smooth muscle actin expression were
reduced at this time point (Figs. 3 and 4). At day 6 all three
parameters were significantly lower than in group A while at
day 10 only the total glomerular cellularity remained lower than
that in rats of group A (Figs. 3 and 4). Double immunostaining
showed that the reduction of glomerular cell proliferation at
days 2 and 6 was largely due to reduced mesangial cell prolif-
eration (Table 1). Thus, the relative contribution of proliferating
mesangial cells (PCNA+, Thy 1.1+) to the total proliferating
cells decreased significantly on these days in heparin treated
rats of group B (Table 1).
Similar findings to those observed in group B were also
obtained during a pilot experiment in which four rats with
anti-Thy 1.1 nephritis were treated with subcutaneous heparin
(at similar doses as used in this study) from day —1 to day 3
after disease induction and compared to four untreated rats with
anti-Thy 1.1 nephritis. This experiment too demonstrated a 53
8% reduction of glomerular cell proliferation at day 6 and a
reduction of matrix expansion (see below).
In glomeruli of rats of group C (anti-Thy 1.1 nephntis, late
heparin treatment) the total cellularity, cell proliferation and
a-smooth muscle actin expression were significantly reduced at
days 6 and 10 of the disease (Figs. 3 and 4). As in group B the
reduction of glomerular cell proliferation at days 6 and 10
appeared to be largely due to reduced proliferation of mesangial
cells (Table 1).
Heparin treatment decreases glomerular immunostaining for
PDGF, PDGF receptor, and bFGF during
mesangioprohferative glomerulonephritis
Immunostaining patterns for PDGF B-chain, PDGF receptor
13-subunit, and bFGF in glomeruli of normal rats and rats with
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Fig. 3. Total cell counts and prol(ferating cells (as defined by immu-
nostaining for the PCNA antigen) per glomerular cross section in
normal rats, untreated rats with anti-Thy 1.1 nephritis (U, group A),
and rats with anti-Thy 1.1 nephritis which received either early (,
group B) or late (0, group C) heparin treatment. *D < 0.05 versus
group A.
Table 1. Double immunostaining for PCNA and the Thy 1.1 antigen
on the mesangial cell surface in normal Wistar rats ("day 0"), rats
with anti-Thy 1.1 nephritis (control), in rats with anti-Thy 1.1
nephritis and heparin treatment from day —2 to day 1 (early heparin),
and in rats with anti-Thy 1.1 nephntis and hepann treatment from
days 2 to 5 (late heparin)
Days after
disease
induction
Control
(group A)
Early
heparin
(group B)
Late
heparin
(group C)
Proliferating, 0 0.2 0.1 — —
mesangial 2 2.7 0.3 0.7 0.la 2.2 0.4
(PCNA+, Thy 6 7.4 0.4 1.9 0.3 2.2 0.3
1.1+) 10 1.0 0.1 1.3 0.2 0.3 0.2
Proliferating, non- 0 0.4 0.1 — —
mesangial 2 1.2 0.3 0.9 0.1 1.3 0.1
(PCNA+, Thy 6 0.7 0.2 1.0 0.2 0.8 0.1
1.1—) 10 0.5 0.1 0.5 0.1 0.3 0.1
Not classifiable 0
2
6
10
0.1 0.0
0.7 0.2
1.0 0.2
0.3 0.0
—
0.2 0.0
0.5 0.2
0.2 0.1
—
0.5 0.1
0.4 o.2
0.1 o.Oa
Data are mean SD. Results are expressed as cells per glomerular
cross section. Due to the different staining technique total PCNA-
positive cells per glomerulus are lower than those detected during
immunoperoxidase staining for PCNA only (Fig. 3).
a P < 0.05 versus group A (Bonferroni t-tests)
4
Fig. 4. Glomerular immunostaining scores (see Methods) for the me-
sangial cell activation marker a-smooth muscle actin in normal rats,
untreated rats with anti-Thy 1.1 nephritis (U, group A), and rats with
anti-Thy 1.1 nephritis which received either early (, group B) or late
(0, group C) heparin treatment. *D < 0.05 versus group A.
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Anti-Thy 1.1 Glomerulonephritisanti-Thy 1.1 nephritis using the same antibodies as employed in
this study have been published previously [6, 25, 34] and were
not different in the present study (data not shown).
During anti-Thy 1.1 nephritis the glomerular immunostaining
scores for PDGF B-chain, PDGF receptor 13-subunit and bFGF
in rats of group A (control) remained either unchanged or
decreased below normal (bFGF) at day 2 of the disease (Fig. 5).
At days 6 and, to a lesser degree, day 10 all three immuno-
staining scores increased above the normal range (Fig. 5).
In glomeruli of rats of group B (early heparin) immunostain-
ing scores for PDGF B-chain were not different from controls at
any time point (Fig. 5). In contrast, the glomerular staining
scores for the PDGF receptor /3-subunit were reduced at days 2
and 6 of the disease (Fig. 5). Immunostaining for bFGF was
significantly reduced at days 6 and 10 in group B (Fig. 5).
In rats of group C (late heparin) the glomerular staining
scores for PDGF B-chain, PDGF receptor /3-subunit and bFGF
were significantly reduced at day 6 (Fig. 5). A significantly
lower staining score for PDGF receptor /3-subunit and bFGF
persisted at day 10 in this group (Fig. 5).
Heparin treatment reduces glomerular immunostaining for
ECM proteins during mesangioproliferarive
glomerulonephritis
In agreement with previously published results employing the
same antibodies as in the present study [3], the immunostaining
of glomeruli for laminin, type I and IV collagen, fibronectin,
heparan sulfate proteoglycan, and entactin/nidogen remained
unchanged as compared to normal rats at day 2 of anti-Thy 1.1
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nephritis, increased markedly at day 6, and decreased again at
day 10 in rats of group A (Fig. 6).
In group B (early heparin) there was a minor, but significant
decrease of the glomerular immunostaining for larninin at day 2
as compared to group A (Fig. 6). None of the other ECM
protein staining scores was altered at this time point (Fig. 6). At
day 6 all ECM staining scores, with the exception of heparan
sulfate proteoglycan, were significantly lower in glomeruli of
group B as compared to group A (Fig. 6). For all ECM proteins
the immunostaining in glomeruli showed high intra-biopsy
variability at day 6, and glomeruli with marked ECM expansion
could be detected adjacent to glomeruli with reduced immuno-
staining. At day 10 of anti-Thy 1.1 nephritis, the immunostain-
ing for the various ECM proteins, with the exception of
entactin, was no longer different between groups B and A (Fig.
6).
In group C (late heparin) the immunostaining scores of
glomeruli for the various ECM proteins, with the exception of
heparan sulfate proteoglycan, were significantly reduced at day
6 (Fig. 6). As in group B, glomerular immunostaining for ECM
proteins was highly variable at this time point. At day 10 only
the glomerular staining scores for heparan sulfate proteoglycan
and entactin were lower in group C in comparison to group A
(Fig. 6).
Effects of heparin treatment on mesangiolysis, glomerular
monocyte/macrophage influx, goat IgG deposition, fibrin
deposition and platelet influx
As shown in Figure 7, marked mesangiolysis was present in
rats of group A at day 2. Mesangiolysis decreased at day 6 and
was no longer present at day 10 (Fig. 7). In contrast, both early
(group B) and late (group C) heparin treatment resulted in
greater, persistent mesangiolysis at days 6 (group B) and 10
(groups B and C; Fig. 7). Microaneurysms were noted at day 10
in 5 to 10% of the glomeruli of group B, and 1 to 5% of the
glomeruli of group C as opposed to <1% of the glomeruli of
group A.
In agreement with previous observations [25, 351, induction
of anti-Thy 1.1 nephritis resulted in an early glomerular influx of
monocytes/macrophages which then slowly decreased during
the course of the disease. This monocyte/macrophage influx
was not affected by early (group B) or late (group C) heparin
treatment (data not shown) and the glomerular monocyte/
macrophage counts were not different from those observed in
untreated rats (group A) at days 2 (9.6 0.5 macrophages per
glomerular cross section), 6 (7.0 0.7) and 10 (6.3 1.4).
Similar to the glomerular macrophage influx, the deposition
of goat IgG in glomeruli after the injection of goat anti-rat
thymocyte plasma was not affected by heparin treatment. At
day 2 glomeruli of all groups exhibited moderate staining (score
in group A: 2.1 0.2), which decreased to weak or absent
staining (score in group A: 0.6 0.1) at day 6, and absent
staining at day 10.
Following the induction of anti-Thy 1.1 nephritis the coagu-
lation cascade was activated in the glomeruli as evidenced by
intense glomerular fibrin/fibrinogen deposition at day 2 in
control rats (group A; glomerular staining score: 2.8 0.1; Fig.
8). Glomerular fibrin/fibrinogen deposition then decreased dur-
ing the course of the disease in rats of group A (score at day 6:
1.4 0.1; score at day 10: 0.4 0.1). In rats of group B and C
this staining pattern was not altered to a significant degree
despite the significant prolongation of the whole clotting time
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Fig. 5. Glomerular immunostaining scores (see Methods) for PDGF
B-chain, PDGF receptor /3-subunit, and bFGF in normal rats, un-
treated rats with anti-Thy 1.1 nephritis (•, group A), and rats with
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3IGlomerular laminin staining
ni 1
a,4
0
C)
Co
0)C
C
Ct
cQ
Cd
E0
C)
2
iGlomerular Type I collagen staining
*
*
— .a.
iGlomewlar type IV collagen stainiii
0
iolomerular tibronectin staining I
p400
CO3
.cCt2
a
2el
E200 p4ci 00 t- IC.)C0 lie
C
p
ICLElCa 2b Ha3j l0)3IlflL T ILP I1IFF 1{ I IcoCD0 Ii
p p - iO15mri1sPG staininj' p 4o ioo F lieg i0)ICE *LEIt I
°' 2F
U) I 0
[-r H5 fl II1F ill i'ri JooIFo Fil ICo i
Nomiat Day2 Day6 DaylO Day6
Anti-Thy 1.1 glomerulonephritis Anti-Thy llglomerulonophritis
DaylO
iftJ
Glomerular entactin staining
Normal
-
Day 2
Floege et al: Heparin and mesangioproliferative nephritis 375
Fig. 6. Glomerular immunostaining scores
(see Methods) for various extracellular matrix
proteins in normal rats, untreated rats with
anti-Thy 1.1 nephritis (U, group A), and rats
with anti-Thy 1.1 nephritis which received
either early (, group B) or late (0, group C)
heparin treatment. *D < 0.05 versus group A.
HSPG = heparan sulfate proteoglycan.
during heparin treatment (see below). In addition to the activa-
tion of the coagulation cascade, the induction of anti-Thy 1.1
nephritis was also associated with a marked glomerular influx of
platelets (Fig. 9). Early heparin treatment (group B) did not
affect the initial platelet influx, but rather led to a longer
persistence of glomerular platelet deposits (Figs. 9, 10). Late
heparin treatment (group C) had no significant influence on the
glomerular platelet influx (Fig. 9).
Basic data
As shown in Table 2, whole blood clotting times in untreated
rats with anti-Thy 1.1 nephritis (group A) did not differ from
those observed in normal rats. Heparin treatment from day —2
until day 1 (group B) resulted in a significant prolongation of the
clotting time at days 0 and 2 (Table 2). Similarly, heparin
treatment from days 2 to 5 (group C) led to a significant
prolongation of the clotting time at days 4 and 6 (Table 2).
Neither the induction of anti-Thy 1.1 nephritis nor late
heparin treatment (group C) had an influence on hematocrits
(Table 2). In contrast, in rats of group B there was a small but
significant drop in hematocrits at days 0, 2, and 4 (Table 2).
Heparin treatment and the intraperitoneal implantation of a
micro-osmotic pump did not significantly affect daily food or
water intake (data not shown).
Discussion
In the present study we have obtained direct evidence that
the administration of standard heparin either prior to or during
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Fig. 7. Mesangiolysis score (see Methods) in normal rats, untreated
rats with anti-Thy 1.1 nephritis (•, group A), and rats with anti-Thy 1.1
nephritis which received either early (, groupB) or late (0, group C)
heparin treatment. *P < 0.05 versus group A.
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Fig. 8. Glomerular immunostaining for fibrinogen in a renal biopsy of
an untreated rat with anti-Thy 1.1 nephritis (group A) at day 2 ("A")
and a normal Wistar rat ("nl"). Compared to the normal rat, marked
glomerular fibrin/fibrinogen deposition is present in the rat with anti-
Thy 1.1 nephritis. Immunoperoxidase stain with methyl green counter-
stain. x400.
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Fig. 9. Glomerular immunostaining score (see Methods) for platelets in
normal rats, untreated rats with anti-Thy 1.1 nephritis (•, group A),
and rats with anti-Thy 1.1 nephritis which received either early (,
group B) or late (, group C) heparin treatment. J3 < 0.05 versus
group A.
the mesangioproliferative phase of anti-Thy 1.1 nephritis results
in a 65% decrease of glomerular cell proliferation. This obser-
vation is in agreement with preliminary data of other authors,
showing that heparin treatment of rats with anti-Thy 1.1 nephri-
tis can reduce both mesangial hypercellularity [36, 37] and the
glomerular incorporation rate of a thymidine analogue, BrdU
[37]. The decrease in glomerular cell proliferation observed in
our study appeared to be largely due to the suppression of
mesangial cell proliferation as indicated by the findings obtained
with double immunostaining for the PCNA antigen and the Thy
1.1 antigen as well as by the observation of reduced glomerular
a-smooth muscle actin expression. We have previously shown
that the glomerular de novo expression of this actin isotype
specifically marks activated and/or proliferating mesangial cells
[21, 38]. Both early and late administration of heparin led to a
long-lasting effect on mesangial cell proliferation, which ex-
tended well beyond the period of heparin administration but
was ultimately reversible (as in the case of day 10 of the early
heparin treatment group). This finding is in contrast to data
obtained in the Habu snake venom model of mesangioprolifer-
ative nephritis, in which heparin had to be present during the
period of mesangial cell proliferation in order to reduce mesan-
gial hypercellularity [13]. Heparin treatment in our study also
resulted in a reduction of the total glomerular cellularity. These
beneficial actions of heparin did not appear to be due to an
effect of heparin on the initial mesangiolysis, since the mesan-
giolysis score, the initial drop of glomerular cell numbers, the
deposition of anti-mesangial cell antibody (goat IgG) as well as
the resultant influx of monocytes/macrophages were not af-
fected to a detectable degree by heparin.
One potential mechanism by which heparin could affect
mesangial cell proliferation in vivo is via its anticoagulant
activity. Thus, factors of the coagulation cascade such as
thrombin as well as factors released from activated platelets
such as PDGF are potent mitogens for mesangial cells in culture
[reviewed in 9]. Previous data [18, 33, 39] as well as the data of
the present study show that glomerular activation of the coag-
ulation pathway and platelet localization indeed occur in anti-
Thy 1.1 nephritis. In platelet-depleted rats we have also ob-
tained direct evidence that platelets are involved in the
initiation of mesangial cell proliferation in this model [19].
However, various observations of the present study argue
against a significant role of the anticoagulant activity of heparin
as being responsible for the reduction of mesangial cell prolif-
eration. Thus, heparin treatment was equally effective no
matter whether it was given early or late during the course of
anti-Thy 1.1 nephritis, while both glomerular fibrin deposition
and platelet influx were maximal during the early phases of the
disease [this study and 34]. Furthermore, at the heparin dosage
chosen, no significant suppression of either glomerular fibrin
deposition or platelet influx could be demonstrated. In fact,
early heparin treatment led to persistence of glomerular platelet
accumulation in group B as compared to group A, which may
relate to the persistent mesangiolysis in group B.
Alternatively, the therapeutic effectiveness of heparin in the
anti-Thy 1.1 nephritis could reside in its antiproliferative activ-
ity. Thus, heparin has been shown to inhibit the proliferation of
cultured glomerular mesangial, visceral epithelial, and endothe-
hal cells [10, 40, 41]. Strong evidence that heparin may exhibit
similar activity in vivo is proposed by studies in which heparin
species, which were devoid of anticoagulant but not of antipro-
liferative activity, were able to ameliorate the progression of
glomerular disease in rats with subtotal renal ablation [42] or
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Fig. 10. Glomerular immunostaining for platelets in a renal biopsy of rats with anti-Thy 1.1 nephritis that were either untreated (A) or had received
heparjn treatment from day —2 to 1 after disease induction (B). Compared to the rat of group A, there is persistence of platelet accumulation in
the glomerulus of the rat of group B (arrows). Immunoperoxidase stain with methyl green counterstain. x400.
Table 2. Whole blood clotting times and hematocrits in rats with untreated anti-Thy 1.1 glomerulonephritis (group A), in rats with anti-Thy
1.1 nephritis and heparin treatment from day —2 to day 1 (group B), and in rats with anti-Thy 1.1 nephritis and heparin treatment
from days 2 to 5 (group C)
Day prior to or
after disease
induction
Whole blood clotting time (minutes) of group Hematocrit (%) of group
A B C A B C
-2 ND 3.4 0.3 ND ND 42 I ND
0 3.2 0.5 7.0 2.4a 3.2 0.4 44 1 39 2 44 I
2 3.6 0.6 5.3 1.2 4.0 1.0 44 2 40 3 45 2
4 4.0 0.7 3.7 0.5 7.2 l.5 44 2 40 ia 42 3
6 3.9 0.6 3.9 0.6 5.6 l.8 43 2 40 3 41 4
10 4.0 1.2 3.8 0.3 3.8 0.6 45 1 41 3 44 2
Data are mean so (N = 5 in group A, N = 6 in groups B and C). Abbreviation ND is not determined.
P < 0.05 versus group A
aminonucleoside nephrosis [14]. In conjunction with our finding
that increased mesangial cell proliferation occurs early after
subtotal renal ablation [6], this suggests that heparin may
indeed exert a beneficial effect in vivo by inhibiting the prolif-
eration of intrinsic glomerular mesangial cells.
Multiple mechanisms have been proposed by which heparin
could inhibit cell proliferation. Studies in vascular smooth
muscle cells, which exhibit various features reminiscent of
mesangial cells [reviewed in 43, 44], have shown that heparin
can synchronize and arrest the cells in the G0 phase of the cell
cycle [45]. Furthermore, heparin decreases the transcription of
protooncogenes expressed in the mid but not early G1 phase
[46] and may thereby interrupt the completion of the cell cycle.
Although only assessed by a semiquantitative scoring sys-
tem, the data of the present study also suggest that heparin
treatment resulted in a reduction of the mesangial expression of
PDGF 13-receptor subunit and bFGF as well as in a minor
decrease of the mesangial expression of PDGF B-chain. In
previous studies we have presented evidence that all three
proteins are overexpressed in anti-Thy 1.1 nephritis and that
bFGF and PDGF may be involved in the initiation and mainte-
nance of mesangial cell proliferation in this model [25, 34, 47],
Heparin can interfere with the PDGF synthesis and actin in
multiple ways. Thus, in vitro heparin decreases PDGF mRNA
transcription [48], binds to PDGF [49], interferes with PDGF
signaling [45], and heparin treatment in vivo can remove platelet
cationic proteins, such as PDGF, from glomeruli [50]. In
contrast to PDGF, the effects of heparin on the biological
actions of bFGF are less consistent. Thus, heparin can cooper-
ate with bFGF to stimulate growth in some cultured cell lines
[51] and it can protect bFGF from denaturation and degradation
[52]. However, heparin infusion can also displace matrix-bound
bFGF and release it into the circulation [53, 54]. The data of the
present study, showing that early heparin treatment effectively
suppressed mesangial cell proliferation, argue against the first
possibility, in which heparin should have amplified the mito-
genic effect of bFGF released from injured mesangial cells [35].
Thus, multiple mechanisms exist by which heparin could inter-
fere with the action of mesangial cell growth factors such as
PDGF and bFGF. However, although heparin may have these
various direct effects on PDGF and bFGF, we cannot exclude
the possibility that decreased expression of these cytokines
may be a secondary phenomenon related to the decrease in
mesangial cell numbers and consequently decreased staining for
intracellular bFGF or PDGF.
Apart from its effects on the cell cycle and on polypeptide
growth factors, another in vitro activity of heparin, which is
likely to be of relevance for the course of anti-Thy 1.1 nephritis,
is the inhibition of mesangial cell migration by heparin and
heparin-like glycosaminoglycans [55]. It is likely that mesangial
cell migration is involved in association with the mesangial cell
proliferation in the remodeling of the mesangium that follows
the mesangiolysis in the Thy 1.1 model. Although it has not
been possible to demonstrate mesangial cell migration in our
B
4
if "if
378 Floege et a!: Heparin and mesangioprol(ferative nephriris
model, the demonstration that there was persistence of mi-
croaneurysms in the heparin-treated rats suggests that heparin
may also be mediating effects on this mesangial cell function. A
similarity in this regard relates to studies in rats with carotid
balloon injury. In these rats heparin treatment not only reduced
the proliferation rate of vascular smooth muscle cells, which in
many ways resemble mesangial cells [reviewed in 43, 441, but it
also abrogated the migration of the smooth muscle cells into the
intima [56].
The third main finding of this study was that heparin also
suppressed the accumulation of a variety of ECM proteins that
accompanies the mesangial cell proliferation in the anti-Thy 1.1
model [3]. This observation is in agreement with findings in
other progressive models of experimental and human glomeru-
lar disease in which heparin treatment resulted in a reduction of
glomerulosclerosis [14, 42, 57—59, reviewed in 60]. Our data
thereby lend further support to the hypothesis that mesangial
cell activation and proliferation may be linked to subsequent
overproduction of ECM proteins and to the development of
glomerulosclerosis [9]. Alternatively, heparin could also exert
direct effects on the cellular production of ECM proteins. Data
derived from cell culture experiments, however, are conflicting
in this respect. While preliminary findings in rat mesangial cells
suggested that heparin decreases the synthesis of collagenous
proteins [61], in vascular smooth muscle cells and endothelial
cells heparin led to an augmentation of fibronectin, thrombo-
spondin and heparan sulfate proteoglycan synthesis [62—64]. In
the present study the glomerular accumulation of heparan
sulfate proteoglycan in heparin treated rats appeared to be
reduced to a lesser degree than that of the other ECM proteins.
This observation argues against the hypothesis of Coffey and
Karnovsky [13] that heparin replaces the heparan sulfate pro-
teoglycan lost from the glomerular basement membrane during
glomerulonephritis and thereby substitutes its anti-proliferative
effect on mesangial cells. Rather, our findings would suggest
that the persistence of heparan sulfate proteoglycan induced by
heparin treatment provides an additional mechanism by which
heparin could inhibit mesangial cell proliferation [10].
So far clinical studies of heparin treatment have mostly
focused on glomerular diseases characterized by acute onset
and evidence of intraglomerular coagulation, such as rapidly
progressive glomerulonephritis, pre-eclampsia or acute al-
lograft rejection [reviewed in 60]. In these studies heparin was
usually given in combination with other agents such as steroids
or cytostatic drugs and no definite conclusions on the effective-
ness of anticoagulant therapy have been reached [60]. Very few
studies have investigated the efficacy of heparin in chronic
glomerulopathies. In a controlled clinical trial in 18 patients
with biopsy proven chronic proliferative glomerulonephritis,
Cade et al [59] were able to show that a monotherapy of daily
subcutaneous heparin injections for one year could improve
glomerular filtration rates. More importantly, in the eight pa-
tients, who underwent pre- and post-treatment renal biopsies,
glomerular hypercellularity had regressed after one year [591.
In summary, the present study shows that a brief course of
heparin treatment, instituted either prior to the initiation of
mesangial cell proliferation or after it has been established, can
exert a marked growth inhibitory effect on mesangial cells in
vivo and can effectively suppress ECM overproduction by these
cells. This observation suggests that cell proliferation and ECM
overproduction are intricately linked events in vivo and also
provides a further rationale for the use of heparin as an
(adjunctive) therapy in mesangioproliferative and progressive
glomerular diseases. In contrast to promising laboratory studies
with neutralizing antibodies against PDGF or transforming
growth factor-/3 (TGF-/3), which also show beneficial effects on
the mesangial cell proliferation and/or matrix expansion in
experimental mesangioproliferative disease [47, 65], heparin is
clinically available. Despite the potential problem of bleeding,
experimental data such as provided in the present study support
continued investigation of a possible role for heparin in the
therapy of proliferative glomerular diseases, particularly if
non-anticoagulant heparin with antimitogenic properties be-
comes available.
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